Jue, 29 de febrero de 2024
Amneal Pharmaceuticals, aligning with Zambon Group, announces an exclusive licensing pact for IPX203 in key European regions. Zambon claim in a press release.
This novel carbidopa/levodopa formulation signifies a leap in Parkinson’s disease management, pending U.S. FDA review.
Zambon, a legacy in healthcare since 1906, will spearhead IPX203’s European regulatory approval and market introduction.
Zambon Group, known for its neurology prowess and XADAGO® success, aims to enrich its Parkinson’s portfolio with IPX203.
The partnership reflects a shared vision for patient-centric healthcare, underscoring both companies’ commitment to global Parkinson’s disease solutions.
With this strategic move, Amneal and Zambon Group endeavor to bring IPX203’s potential benefits to the European Parkinson’s community, furthering their mission to improve patient lives.
Spanish 
English 
German 
French 
Arabic